KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. (KALV) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · KALV · as of Mar 31, 2025
Ownership Breakdown
138
Institutional Holders
▲ 7 vs Q4
$640.39M
Total Inst. Value
▲ $172.98M vs Q4
53.24M
Shares Outstanding
freeFloat 71.71%
54.92M
13F Shares Held
▼ 269,526 vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
KALV largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VR ADVISER, LLC pharmaceutical preparations | 6.70M | 12.74% | 12.74% | $77.36B | May 15, 2025 | ▲ 454.3K |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 4.94M | 9.39% | 9.39% | $57.03B | May 15, 2025 | ▲ 48.0K |
SUVRETTA CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 4.91M | 9.33% | 9.33% | $56.70B | May 15, 2025 | — held |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. pharmaceutical preparations | 4.89M | 9.29% | 9.29% | $56.41B | May 15, 2025 | — held |
VESTAL POINT CAPITAL, LP pharmaceutical preparations | 4.75M | 9.03% | 9.03% | $54.83B | May 15, 2025 | ▼ 18.7K |
CAPITAL WORLD INVESTORS pharmaceutical preparations | 3.18M | 6.04% | 6.04% | $36.67B | May 12, 2025 | ▼ 196.5K |
BLACKROCK, INC. pharmaceutical preparations | 3.15M | 5.99% | 5.99% | $36.37B | May 2, 2025 | ▲ 287.7K |
VANGUARD GROUP INC pharmaceutical preparations | 2.30M | 4.37% | 4.37% | $26.53B | May 9, 2025 | ▲ 43.4K |
SILVERARC CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 1.70M | 3.23% | 3.23% | $19.61B | May 14, 2025 | ▲ 1.09M |
WOODLINE PARTNERS LP pharmaceutical preparations | 1.62M | 3.07% | 3.07% | $18.67B | May 15, 2025 | ▲ 329.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
20
Increased
+3.33M shares9
New Positions
first time holders15
Decreased
−2.65M shares0
Sold Out
fully exitedNet shares change (top 50)
+679.8K
+3.33M / −2.65M
Net new holders
+14
9 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
KALV insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
17
Buy transactions
34
Sell transactions
0.50
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Yea Christopher CHIEF DEVELOPMENT OFFICER | May 27, 2026 | Sale | 33,800 | $26.78 | $905.2K | 229.9K | Form 4 ↗ |
Yea Christopher CHIEF DEVELOPMENT OFFICER | May 26, 2026 | Sale | 1,966 | $26.78 | $52.6K | 229.9K | Form 4 ↗ |
Sweeny Nicole Chief Commercial Officer | May 26, 2026 | Sale | 1,489 | $26.78 | $39.9K | 59.3K | Form 4 ↗ |
Audhya Paul K. CHIEF MEDICAL OFFICER | May 26, 2026 | Sale | 2,239 | $26.78 | $60.0K | 150.3K | Form 4 ↗ |
Palleiko Benjamin L CHIEF EXECUTIVE OFFICER | May 22, 2026 | Sale | 10,926 | $26.78 | $292.6K | 480.0K | Form 4 ↗ |
Sweeny Nicole Chief Commercial Officer | May 22, 2026 | Sale | 1,861 | $26.78 | $49.8K | 55.8K | Form 4 ↗ |
Yea Christopher CHIEF DEVELOPMENT OFFICER | May 22, 2026 | Sale | 2,358 | $26.78 | $63.2K | 228.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
KalVista Pharmaceuticals, Inc. (KALV) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 28.29%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of KalVista Pharmaceuticals, Inc. is VR ADVISER, LLC, holding approximately 6.70 million shares — equal to 12.74% of outstanding shares — as of March 31, 2025.
A total of 138 institutional investors currently hold KALV stock, with a combined institutional value of approximately $640,391,431 as of the most recent 13F filing period.
Frequently asked questions
KALV ownershipKalVista Pharmaceuticals, Inc. (KALV) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is VR ADVISER, LLC with a 12.74% stake. Company insiders hold 28.29%. Data sourced from SEC Form 13F as of March 31, 2025.